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A B S T R A C T
Background
Parenteral nutrition solutions, artificial formulas, and human breast milk contain insufficient iodine to meet recommended intakes
for preterm infants. Iodine deficiency may exacerbate transient hypothyroxinaemia in preterm infants and this may be associated with
adverse neonatal and longer-term outcomes.
Objectives
To assess the evidence from randomised controlled trials that dietary supplementation with iodine reduces mortality and morbidity in
preterm infants.
Search methods
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL
2018, Issue 1), Ovid MEDLINE, Ovid Embase, Ovid Maternity & Infant Care Database, and CINAHL to February 2018. We
searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials
and quasi-randomised trials.
Selection criteria
Randomised or quasi-randomised controlled trials that compared supplementing enteral or parenteral feeds with iodine (as iodide salt)
versus placebo or no supplementation in preterm infants.
Data collection and analysis
Two review authors independently assessed trial eligibility and risk of bias, and extracted data.We analysed treatment effects as described
in the individual trials and reported risk ratios (RR) and risk differences for dichotomous data, and mean differences (MD) for
continuous data, with 95% confidence intervals (CI). We used a fixed-effect model in meta-analyses and planned to explore potential
causes of heterogeneity in sensitivity analyses. We used the GRADE approach to assess the quality of evidence.
1Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Two randomised controlled trials fulfilled the eligibility criteria. Both trials used methods to limit bias including allocation concealment
and blinding of clinicians and investigators to the allocated intervention. The trials enrolled 1394 infants. One trial recruited 1273
participants. Most participants were born very preterm (less than 32 weeks’ gestation) and about one-third were extremely preterm
(less than 28 weeks’ gestation). Analyses found no effect of iodine supplementation on mortality before hospital discharge (typical RR
1.01, 95% CI 0.72 to 1.42; 2 studies, 1380 infants) or on neurodevelopmental assessments at two years post-term (Bayley Scales of
Infant and Toddler Development, Third Edition main domain composite scores: cognitive: MD -0.30, 95% CI -2.44 to 1.84; motor:
MD 0.20, 95% CI -2.15 to 2.55; language: MD -0.10, 95% CI -2.50 to 2.30; 1 study, 1259 infants). There were no differences in
the proportion of infants who died or had a composite score less than 85 in any main Bayley domain (RR 1.05, 95% CI 0.94 to 1.17;
1 study, 1259 infants), or had visual impairment (RR 0.63, 95% CI 0.28 to 1.45; 1 study, 1092 infants) or auditory impairment (RR
1.05, 95% CI 0.51 to 2.16; 1 study, 1093 infants). Using GRADE methods, we assessed the evidence for the effects on mortality and
neurodevelopment outcomes as high-certainty.
Authors’ conclusions
The available trial data, predominantly from one large, high-quality multicentre study published in 2017, do not show any evidence
of beneficial effects of iodine supplementation for preterm infants. Given the high certainty of these estimates of effect, further trials
of this intervention in this population are unlikely to be considered research priorities.
P L A I N L A N G U A G E S U M M A R Y
Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Review question: Does giving preterm infants iodine supplements reduce their risk of dying or improve their brain development?
Background: Infants born preterm (several weeks early) may not receive the recommended amounts of iodine in their diet, as both
preterm human breast milk and nutrition given via a drip in hospitals do not contain enough iodine to meet their heightened needs.
Deficiency of iodine may affect the production of thyroid hormones that are important for brain and lung development in newborn
infants. Given concerns that iodine deficiency may be harmful, we reviewed all the available evidence from clinical trials that assessed
the effects of giving preterm infants iodine supplements.
Study characteristics: The evidence is up to date as of February 2018. We found two relevant trials (including 1394 infants). Both
trials used reliable methods to ensure that their findings were not biased.
Key results: Analysis of data from these trials showed that iodine supplements for preterm infants does not affect the chances of dying
or improve longer-term brain development. This evidence was highly reliable.
Conclusions:The currently available evidence indicates conclusively that routine supplemental iodine does not have important benefits
for preterm infants.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Iodine supplementation compared to control for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Outcomes of participants
(studies)
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with control Risk difference with Iodine
supplementation
Mortality before hospital
discharge
1380
(2 RCTs)
⊕⊕⊕⊕
High
RR 1.01 (0.72 to 1.42) Study populat ion
87 per 1000 1 more per 1000
(24 fewer to 37 more)
Bayley- III Cognitive com-
posite score at 2 years of
age corrected for prematu-
rity
1259
(1 RCT)
⊕⊕⊕⊕
High
- The mean Bayley-III Cognit ive
composite score at 2 years of
age corrected for prematurity
was 0
MD 0.3 lower
(2.44 lower to 1.84 higher)
Bayley- III Motor composite
score at 2 years of age cor-
rected for prematurity
1259
(1 RCT)
⊕⊕⊕⊕
High
- The mean Bayley-III Motor
composite score at 2 years of
age corrected for prematurity
was 0
MD 0.2 higher
(2.15 lower to 2.55 higher)
Bayley- III Language com-
posite score at 2 years of
age corrected for prematu-
rity
1259
(1 RCT)
⊕⊕⊕⊕
High
- The mean Bayley-III Lan-
guage composite score at 2
years of age corrected for
prematurity was 0
MD 0.1 lower
(2.50 lower to 2.30 higher)
Low score in any main Bay-
ley domain (< 85) or death
1259
(1 RCT)
⊕⊕⊕⊕
High
RR 1.05
(0.94 to 1.17)
Study populat ion
490 per 1000 25 more per 1000
(29 fewer to 83 more)
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Bayley- III: Bayley Scales of Infant and Toddler Development, Third Edit ion; CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
Transient hypothyroxinaemia of prematurity is themore common
thyroid dysfunction in preterm infants (Rooman 1996; Williams
2008; Delahunty 2010). It is characterised by a temporary post-
natal reduction in plasma levels of free thyroxine (T4) and tri-
iodothyronine (T3). Unlike congenital hypothyroidism, plasma
levels of thyroid-stimulating hormone (TSH) remain normal or
low (Williams 2008). The incidence, and degree and duration, of
hypothyroxinaemia is inversely related to birth weight and gesta-
tional age and positively correlated with illness severity (particu-
larly the severity of respiratory distress syndrome) (Reuss 1997).
Transient hypothyroxinaemia, when defined as plasma T4 levels
less than 40 µg/L, occurs in about 40% in infants born at 23 weeks’
gestation and about 10% in infants born at 28 weeks’ gestation
(Reuss 1996).
Thyroid hormones play critical roles in postnatal transition pro-
cesses and in foetal and infant growth and development (Forhead
2014; Velasco 2018). Thyroid hormones may act synergistically
with corticosteroids to accelerate surfactant production and re-
duce the severity of respiratory distress syndrome and associated
complications (need for mechanical ventilation, air leak, chronic
lung disease (CLD)) in preterm infants (Liggins 1988). Thyroid
hormones are essential for foetal and infant brain growth and de-
velopment and concern exists that hypothyroxinaemiamay impair
neurodevelopment in preterm infants, and particularly in very or
extremely preterm infants. Observational studies have suggested a
link between transient hypothyroxinaemia and poorer neurodevel-
opmental outcomes including cognitive delay and cerebral palsy
(Meijer 1992; DenOuden 1996; Lucas 1996; Reuss 1996). How-
ever, some studies found no strong associations when potential
confounders such as gestational age and illness severity are ac-
counted for (Scratch 2014; Hollanders 2015; Hollanders 2016).
Iodine requirements
The aetiology of transient hypothyroxinaemia in preterm infants is
multifactorial. As well as the contribution of non-thyroidal illness
and immaturity of the hypothalamic-pituitary-thyroid axis, iodine
deficiencymay contribute (Ares 1997;Murphy 2004). The neona-
tal thyroid gland is highly sensitive to iodine deficiency. Preterm
infants do not have a substantial iodine pool and must renew its
existing stores to meet thyroidal hormone requirements. Nutrient
balance studies in healthy preterm infants indicate that daily io-
dine intakes of at least 30 µg/kg bodyweight are needed to main-
tain a positive balance (Ares 1997). One international consensus
statement recommends daily iodine enteral intakes of 11 µg/kg to
55 µg/kg for healthy preterm infants (Agostoni 2010).
The typical iodine content of artificial formula ranges from about
70 to 250 µg/L (Belfort 2012). Maternal breast milk contains
about 100 to 150 µg/L (depending on the dietary iodine intake
of the mother), and commercially available breast-milk fortifiers
do not contain iodine (Koo 2017). Enterally fed preterm infants,
therefore, may not achieve the recommended intake of iodine,
especially during the firstweeks of postnatal life when feed volumes
are still being advanced (Ares 1997; Belfort 2012).
Preterm infants who are predominantly parenterally fed are at
greater risk of negative iodine balance. Most commercially avail-
able parenteral nutrition solutions contain less iodine than breast
milk or formula (Belfort 2012). The American Society for Clin-
ical Nutrition has recommended daily parenteral iodine intakes
of about 1 µg/kg (Belfort 2012). This conservative recommen-
dation is influenced by an assumption that most parenterally fed
preterm infants will absorb iodine transcutaneously from topical
iodinated antiseptic solutions. However, the use of iodinated an-
tiseptics for preterm infants has decreased due to concern that
excessive transcutaneous iodine intake (greater than 100 µg/kg/
day)may cause early acquired neonatal hypothyroidism (Smerdely
1989; Aitken 2014; Kieran 2018). Evidence exists that parentally
fed very preterm infants who have not been exposed to other
sources of iodine achieve daily iodine intakes of about 1 µg/kg to
3 µg/kg and are in negative iodine balance during the first week
of postnatal life (Ibrahim 2003).
Description of the intervention
Iodine can be administered enterally as iodide salt and is well-ab-
sorbed in the stomach and duodenum as well as being available for
parenteral administration. Iodide is carried within the circulation,
trapped in the thyroid follicle, and oxidised to iodine, which is
then used to iodinate the tyrosine residues within thyroglobulin.
Proteases cleave the residues to release thyroid hormones, which
are formed through coupling of the iodotyrosyl residues (Forhead
2014).
How the intervention might work
Iodine deficiency may contribute to the pathogenesis of tran-
sient hypothyroxinaemia which may have adverse consequences
for physiological postnatal transition and neurodevelopment dur-
ing a critical phase of brain growth. Supplementing the diet or
intake of preterm infants with iodide to meet recommended re-
quirements could reduce the incidence, duration, and severity of
transient hypothyrinoxinaemia and improve neurodevelopment
and other outcomes.
Why it is important to do this review
Given the potential for negative iodine balance to cause hypothy-
roxinaemia and adverse neurodevelopmental and other outcomes,
especially in very or extremely preterm infants, we reviewed the
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available evidence from randomised trials of iodine supplementa-
tion for preventing morbidity and mortality in preterm infants.
O B J E C T I V E S
To assess the evidence from randomised controlled trials that di-
etary supplementation with iodine reduces mortality and morbid-
ity in preterm infants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled trials using random or quasi-random patient alloca-
tion. Cluster-randomised trials (where the neonatal unit, rather
than the individual patient, is randomised) were eligible for inclu-
sion provided they met the other inclusion criteria.
Types of participants
Preterm infants (less than 37 weeks’ gestation at birth).
Types of interventions
Supplementation with iodine (iodide: 30 µg/kg bodyweight per
day or greater) compared with placebo or no supplementation.
The comparison groups should have received the same nutrient
input and other treatments apart from the level of iodide input.
Types of outcome measures
Primary outcomes
• Neonatal mortality and mortality prior to hospital
discharge.
• Neurodevelopmental outcomes assessed by a validated test
after 12 months’ post-term: neurological evaluations,
developmental scores, and classifications of disability, including
auditory and visual disability.
Secondary outcomes
• Measures of the respiratory morbidity including:
◦ duration of mechanical ventilation;
◦ incidence of air leaks;
◦ incidence of CLD (supplemental oxygen requirement
at 36 weeks’ postmenstrual age).
• Other neonatal morbidity including incidence of:
◦ necrotising enterocolitis (NEC);
◦ retinopathy of prematurity (ROP);
◦ persistent patent ductus arteriosus (PDA);
◦ late-onset infection.
• Biochemical measures of thyroid function and iodine status
such as plasma levels of T4 (free and total), T3, or TSH.
Search methods for identification of studies
We used the criteria and standard methods of Cochrane and
Cochrane Neonatal (see the Cochrane Neonatal search strategy).
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL 2018, Issue 1), OvidMEDLINE (1946 to 27 Febru-
ary 2018), Ovid Embase (1974 to 27 February 2018), Ovid Ma-
ternity & Infant Care Database (1971 to February 2018), and
the Cumulative Index to Nursing and Allied Health Literature
(CINAHL; 1982 to 27 February 2018) using a combination of
text words and MeSH terms described in Appendix 1. We limited
the search outputs with the relevant search filters for clinical trials
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2017). We applied no language restric-
tions.
We searched ClinicalTrials.gov and the World Health Organiza-
tion’s International Trials Registry and Platform (www.who.int/
ictrp/en/) for completed or ongoing trials.
Searching other resources
We examined reference lists in previous reviews and included stud-
ies. We searched the proceedings of the annual meetings of the
Pediatric Academic Societies (1993 to 2018), European Society
for Paediatric Research (1995 to 2017), Royal College of Paedi-
atrics and Child Health (2000 to 2018), and Perinatal Society of
Australia andNewZealand (2000 to 2018). Trials reported only as
abstracts were eligible if sufficient information was available from
the report, or from contact with the authors, to fulfil the inclusion
criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
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Selection of studies
We screened the title and abstract of all studies identified by the
search. Two review authors (VW, JVEB) independently assessed
the full-text articles of all potentially relevant trials. We excluded
those studies that did not meet all of the inclusion criteria and we
stated the reason for exclusion in the Characteristics of excluded
studies table. We discussed any disagreements until consensus was
achieved. We recorded the selection process in sufficient detail to
complete a PRISMA flow diagram.
Data extraction and management
Two review authors (VW, JVEB) independently extracted data
using a data collection form to aid extraction of information on
design, methodology, participants, interventions, outcomes, and
treatment effects from each included study. We assessed the data
collection form for usability prior to data extraction. We discussed
any disagreements until we reached consensus. If data from the
trial reports were insufficient, we contacted the trialists for further
information.
Assessment of risk of bias in included studies
Two review authors (VW, JVEB) independently assessed the risk
of bias (low, high, or unclear) of included trials using theCochrane
‘Risk of bias’ tool for the following domains (Higgins 2017;
Appendix 2):
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective reporting (reporting bias).
We discussed any disagreements until we reached consensus or
we consulted a third review author. See Appendix 2 for detailed
description of risk of bias for each domain.
Measures of treatment effect
We calculated risk ratio (RR) and risk difference (RD) for dichoto-
mous data and mean difference (MD) for continuous data, with
95% confidence intervals (CI). When it was deemed appropriate
to combine two or more study arms, we obtained the treatment
effects from the combined data using themethods described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2017). We planned to determine the number needed to treat for
an additional beneficial outcome (NNTB) or additional harmful
outcome (NNTH) for a statistically significant difference in the
RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials and the neonatal unit (or subunit) for cluster-
randomised trials. For cluster-randomised trials, we planned to
undertake analyses at the level of the participant while accounting
for the clustering in the data using the methods recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2017).
Dealing with missing data
Where data were missing, and could not be derived, we attempted
to:
• contact the original study investigators to request the
missing data;
• where possible, impute missing standard deviations (SDs)
using the coefficient of variation or calculate from other available
statistics including standard errors, CIs, t values, and P values;
• (if the data were thought to be missing at random) analyse
the data without imputing any missing values;
• (if this could not be assumed) impute the missing outcomes
with replacement values, assuming all to have a poor outcome.
We planned sensitivity analyses to assess any changes in the direc-
tion or magnitude of effect resulting from data imputation.
Assessment of heterogeneity
Two review authors (VW, WM) assessed clinical heterogeneity
with a meta-analysis conducted only when both review authors
agreed that study participants, interventions, and outcomes were
sufficiently similar.
We examined the treatment effects of individual trials and hetero-
geneity between trial results by inspecting the forest plots. We cal-
culated the I² statistic for each analysis to quantify inconsistency
across studies and described the percentage of variability in effect
estimates that may have been due to heterogeneity rather than to
sampling error. If we detected moderate or high heterogeneity (I²
greater than 50%), we planned to explore the possible causes (e.g.
differences in study design, participants, interventions, or com-
pleteness of outcome assessments).
Assessment of reporting biases
If more than 10 trials were included in ameta-analysis, we planned
to examine a funnel plot for asymmetry.
Data synthesis
We used a fixed-effect model for meta-analysis (as per Cochrane
Neonatal recommendations). Where moderate or high hetero-
geneity existed, we planned to examine the potential causes in
subgroup and sensitivity analyses.
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Certainty of evidence
We assessed the certainty of evidence for the main comparisons
at the outcomes level using the GRADE approach for the fol-
lowing outcomes: mortality and neurodevelopmental outcomes
(Schünemann 2013; see Appendix 3).
Two review authors independently (VW, WM) assessed the cer-
tainty of the evidence for each of these outcomes. We considered
evidence from randomised controlled trials as high quality but
downgraded one level for serious (or two levels for very serious)
limitations based upon the following: design (risk of bias), con-
sistency across studies, directness of the evidence, precision of es-
timates, and presence of publication bias. We used GRADEpro
GDT to create a ’Summary of findings’ table to report the cer-
tainty of the evidence.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses by:
• gestation: extremely preterm (less than 28 weeks’ gestation)
versus very preterm (28 to 31 weeks’ gestation) infants versus
preterm infants (32 weeks’ gestation or later);
• indication: prophylactic versus therapeutic use (to treat
iodine deficiency or hypothyroxinaemia).
Sensitivity analysis
We planned sensitivity analyses to determine if the findings were
affected by including only studies of adequate methodology (low
risk of bias), defined as adequate randomisation and allocation
concealment, blinding of intervention and measurement, and less
than 10% loss to follow-up.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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We included one new trial (Williams 2017), in addition to the
existing trial (Rogahn 2000).
We identified no ongoing trials.
Included studies
Rogahn 2000: the investigators randomly allocated 121 infants
born at less than 33 weeks’ gestation to receive either iodide-sup-
plemented (272 µg/L) formula or the same formula without io-
dide supplementation. This strategy was designed to provide an
iodine intake of 40 µg/kg/day to 50 µg/kg/day in the interven-
tion group versus 12 µg/kg/day to 16 µg/kg/day in the control
group. Infants were allocated to receive the trial formulas until 40
weeks’ postmenstrual age. The primary outcomes (on which the
sample size calculationwas based) were the plasma levels of thyroid
hormones. Some inhospital clinical outcome data were reported.
Neurodevelopment and cognitive function were not assessed.
Williams 2017: the investigators randomly allocated 1273 infants
born at less than 31 weeks’ gestation to receive either sodium
iodide (75 µg/L) or sodium chloride (75 µg/L) given parenterally
or enterally (as indicated) at a dose of 30 µg/kg/day. Infants were
recruited less than 42 hours after birth andwere allocated to receive
the trial solution daily until 34 weeks’ postmenstrual age. The
primary outcome was neurodevelopmental status defined by the
Bayley Scales of Infant and Toddler Development, Third Edition
(Bayley-III) main domains (cognitive, motor, language) at two
years’ post-term. AminimumBayley-III score for each domainwas
awarded if an infant died before neurodevelopmental assessment
or was too disabled to make an assessment meaningful. Secondary
outcomes were the subtests of the Bayley-III; Bayley-III analysed
as a dichotomous outcome (death or a Bayley-III score less than
85 in any of the main domains versus a Bayley-III score 85 or
greater); plasma levels of T4, TSH, and thyroid-binding globulin
(TBG) on postnatal days 7, 14, 28, and at 34 weeks’ gestation;
incidence of NEC, ROP, PDA, CLD, and late-onset infection;
and prescribed drug usage.
Excluded studies
We excluded five studies (Bouhouch 2013; Wang 2013; Belykh
2014; Karto lu 2014; Mohammed 2015). Reasons for exclusion
are presented in the Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Methodological quality was generally high.
Allocation
Rogahn 2000: the random sequence was derived from a random
number table and concealed within sealed opaque envelopes (low
risk).
Williams 2017: randomisationwas achieved through a secure web-
site and used a bespoke minimisation algorithm to ensure balance
across cross groups for recruiting site, gender, and gestational age.
Infants from multiple births were assigned individually (low risk).
Blinding
Rogahn 2000: the intervention and control formula milks were
identical in appearance and the iodine levels were not known to
parents, caregivers, or outcome assessors (low risk).
Williams 2017: the intervention and control solutionswere identi-
cal in appearance and the research teammembers, parents, neona-
tal unit staff, and pharmacy staff were blinded (low risk).
Incomplete outcome data
Rogahn 2000: complete outcome data up to 40 weeks’ postmen-
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strual age were available for 114/121 infants. Biochemical data
were not available for six infants withdrawn from the study (rea-
sons not stated) and for one infant who died during the study pe-
riod. The primary analyses were by intention-to-treat (low risk).
Williams 2017: outcome assessment was achieved for 631/637
infants in the iodide supplementation group and 628/636 infants
in the control group. Fourteen infants (six infants in the iodide
supplementation group and eight infants in the placebo group)
were withdrawn with no data available for analyses (low risk).
Selective reporting
Rogahn 2000: the published study did not report number of days
of continuous positive airways pressure, number of days until com-
pleting the study, duration of parenteral feeding and human milk
feeding in days, and daily milk intake (unclear risk).
Williams 2017: secondary outcomes were reported as per the pro-
tocol with the exception of days of endotracheal intubation and
days of continuous positive airways pressure (unclear risk).
Effects of interventions
See: Summary of findings for the main comparison Iodine
supplementation compared to control for the prevention of
mortality and adverse neurodevelopmental outcomes in preterm
infants
1. Mortality (outcome 1.1)
Meta-analysis showed no significant difference in the incidence of
death before hospital discharge: typical RR 1.01 (95% CI 0.72 to
1.42); typical RD 0.00 (95% CI -0.03 to 0.03); I² = 0%, 2 trials,
1380 participants; high-certainty evidence (Analysis 1.1; Figure
4).
Figure 4. Forest plot of comparison: 1 Iodine supplementation versus control, outcome: 1.1 Mortality
before hospital discharge.
2. Neurodevelopmental outcomes (outcomes 1.2 to 1.7)
Rogahn 2000 did not assess neurodevelopmental outcomes.
Williams 2017 found no significant difference in Bayley-III com-
posite scores across the three domains:
• Cognitive: MD -0.30 (95% CI -2.44 to 1.84); 1 trial, 1259
participants; high-certainty evidence (Analysis 1.2; Figure 5);
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Figure 5. Forest plot of comparison: 1 Iodine supplementation versus control, outcome: 1.2 Bayley-III
Cognitive score at 2 years of age corrected for prematurity.
• Motor: MD 0.20 (95% CI -2.15 to 2.55); 1 trial, 1259
participants; high-certainty evidence (Analysis 1.3; Figure 6);
Figure 6. Forest plot of comparison: 1 Iodine supplementation versus control, outcome: 1.3 Bayley-III
Motor composite score at 2 years of age corrected for prematurity.
• Language: MD -0.10 (95% CI -2.50 to 2.30); 1 trial, 1259
participants; high-certainty evidence (Analysis 1.4; Figure 7)
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Figure 7. Forest plot of comparison: 1 Iodine supplementation versus control, outcome: 1.4 Bayley-III
Language composite score at 2 years of age corrected for prematurity.
There was no difference in the proportion of infants who died or
had a composite score less than 85 in any main Bayley domain:
RR 1.05 (95% CI 0.94 to 1.17); 1 trial, 1259 participants; high-
certainty evidence (Analysis 1.5; Figure 8).
Figure 8. Forest plot of comparison: 1 Iodine supplementation versus control, outcome: 1.5 Low score in
any main Bayley domain (less than 85) or death.
Williams 2017 found no differences in rates of:
• visual impairment: RR 0.63 (95% CI 0.28 to 1.45); 1 trial,
1092 participants (Analysis 1.6);
• auditory impairment: RR 1.05 (95% CI 0.51 to 2.16); 1
trial, 1093 participants (Analysis 1.7).
3. Respiratory morbidity (outcomes 1.8 to 1.9)
Rogahn 2000 found no difference in the duration of mechanical
ventilation: median difference 0 days (SD not reported). Williams
2017 did not report the duration of mechanical ventilation.
Williams 2017 found a lower incidence of air leaks (pneumotho-
rax) in the iodide group: RR 0.50 (95% CI 0.31 to 0.80); RD -
0.04 (95% CI -0.07 to -0.01); NNTH 25 (95% CI 14 to 100);
1 trial, 1257 participants (Analysis 1.8). Rogahn 2000 did not
report the incidence of air leaks.
Meta-analyses found no significant differences in:
• CLD: typical RR 1.07 (95% CI 0.94 to 1.22); I² = 75%, 2
trials, 1377 participants (Analysis 1.9).
4. Other neonatal morbidity (outcomes 1.10 to 1.13)
Williams 2017 found no differences in the incidences of:
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• NEC: RR 1.24 (95% CI 0.98 to 1.56); 1 trial, 1259
participants (Analysis 1.10);
• ROP: RR 0.97 (95% CI 0.64 to 1.49); 1 trial,1257
participants (Analysis 1.11);
• PDA: RR 0.98 (95% CI 0.83 to 1.16); 1 trial,1259
participants (Analysis 1.12);
• Late-onset infection: RR 1.09 (95% CI 0.96 to 1.24); 1
trial,1259 participants (Analysis 1.13).
Rogahn 2000 did not report the incidence of NEC, PDA, ROP,
or late-onset infection.
5. Biochemical measures of thyroid function (outcomes 1.14
to 1.15)
Rogahn 2000 did not report any statistically significant differences
in the plasma levels of T4, T3, or TSH measured up to 40 weeks’
postmenstrual age.
Williams 2017 did not report any significant differences in plasma
levels of T4, TSH, or TBG up to 34 to 36 weeks’ postmenstrual
age.
Meta-analyses found no significant differences at 34 to 36 weeks’
postmenstrual age in plasma levels of:
• total T4: MD 0.29 (95% CI -1.51 to 2.09) nmol/L; I² =
0%, 2 trials, 1121 participants (Analysis 1.14);
• TSH: MD 0.05 (95% CI -0.09 to 0.18) mU/L; I² = 8%, 2
trials, 1119 participants (Analysis 1.15).
Subgroup analyses
Both trials assessed the effect of prophylactic rather than ther-
apeutic iodine supplementation. Williams 2017 reported that a
prespecified subgroup analysis of infants who had hypothyroxi-
naemia (plasma T4 less than 10th percentile on postnatal day 7,
14, or 28; 288 participants) versus infants without hypothyroxi-
naemia found no significant differences in scores across the Bay-
ley-III main domains.
All participants in Williams 2017 were born before 31 weeks’
gestation and those in Rogahn 2000 before 33 weeks’ gestation.
The data available did not allow further subgroup analyses by
birth weight and gestational age to be undertaken. Williams 2017
reported that there was no evidence of a difference in the effect of
iodide versus placebo on the mean Bayley-III main domain scores
by gestational age groups (less than 26, 26 to 27, or 28 to 30
weeks).
D I S C U S S I O N
Summary of main results
We identified two eligible randomised controlled trials that in-
cluded1394preterm infants bornbefore 33weeks’ gestation.Most
infants (1273/1394) participated in one largemulticentre trial un-
dertaken in theUKduring the past decade (Williams 2017). These
trials found no evidence that iodine supplementation affected the
incidence of mortality, adverse neurodevelopmental outcomes, or
major neonatal morbidity in preterm infants.
Overall completeness and applicability of
evidence
The previous version of this review included one small randomised
controlled trial (121 participants; Rogahn 2000). The available
data were insufficient to determine whether iodine supplemen-
tation affected mortality and morbidity in preterm infants. The
review concluded that data from “a large pragmatic randomised
controlled trial [were needed] to determine if iodine supplemen-
tation, started within a few days after birth, prevents morbidity
and mortality in preterm infants” (Ibrahim 2006). One large mul-
ticentre randomised controlled trial has now provided these data
(Williams 2017). Inclusion of this trial in the review increased
the total number of participants included in assessments of iodine
supplementation from 121 to 1394. This included a substantial
proportion (34%) of extremely preterm (less than 28 weeks’ ges-
tation) infants, the group at greatest risk of transient hypothyrox-
inaemia.
Data on neurodevelopmental outcomes, which were not reported
by Rogahn 2000, were available from Williams 2017. These as-
sessments used a validated and accepted tool (Bayley-III). Asses-
sors were unaware of the groups to which the participants had
been allocated. Outcome data were available for more than 90% of
the cohort (balanced across the intervention and placebo groups).
The analyses found no effects of iodine supplementation on the
composite scores for Bayley-III assessments in major domains.
The 95% CI for the estimates of effect size estimates were narrow
indicating that modest, though potentially important, effects on
motor, language, or cognitive development was unlikely to have
been missed. We were unable to undertake a subgroup analysis of
extremely preterm or extremely low birth weight infants with the
available data. However, Williams 2017 reported that the lack of
effect of iodine supplementation on mortality and neurodevelop-
ment was consistent across gestational age bands (less than 26, 26
to 27, or 28 to 30 weeks).
Meta-analyses of the effect on major neonatal morbidity (NEC,
CLD, ROP, late-onset infection) found no evidence of benefit of
supplemental iodine versus placebo. Data fromWilliams 2017 in-
dicated a substantial reduction in the risk of pneumothorax as-
sociated with iodine supplementation. However, given this was
one of many secondary outcomes analysed, this finding should be
interpreted with caution.
Both of the included trials assessed the effect of prophylac-
tic (empirical) iodine supplementation rather than therapeu-
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tic (indicated) supplementation for infants with a diagnosis of
hypothyroxinaemia, the group for whom the putative benefits
of the intervention might be most likely (Williams 2011; van
Wassenaer-Leemhuis 2014). Williams 2017 reported a prespeci-
fied subgroup analysis that found no difference in the effect size in
those infants with versus without evidence of hypothyroxinaemia.
This finding is consistent with data from both trials which showed
that iodine supplementation had no effect of biochemical mea-
sures of thyroid function including plasma levels of T4 or TSH.
Quality of the evidence
The included trials were high quality with both using methods to
limit bias including ensuring allocation concealment and blinding
of parents, clinicians, and investigators. Adherence to the inter-
vention was high. In Williams 2017, less than 5% of infants were
withdrawn from the trial during the intervention period (and their
data were collected for reporting of intention-to-treat analyses).
Both trials achieved near-complete primary outcome assessment.
The meta-analyses (where data from both trials could be com-
bined) were dominated by the larger trial but none of the analyses
had evidence of statistical heterogeneity. Analyses generated pre-
cise and consistent effect size estimates that indicate that impor-
tant effects were unlikely to have been missed. Consequently, the
overall certainty of the evidence as assessed by GRADE methods
was high for the primary outcomes (Summary of findings for the
main comparison).
Potential biases in the review process
The main concern with the review process was that the findings
may have been subjected to publication or other reporting biases.
To minimise potential publication bias, we included non-English
language publications and we searched conference proceedings
and trial registries for unreported, unpublished, or ongoing trials.
As only two trials were eligible in our review, however, there were
insufficient data to explore potential publication or reporting bias
through examination of asymmetry in funnel plots.
Agreements and disagreements with other
studies or reviews
Cochrane Reviews of trials of postnatal thyroid hormone supple-
mentation, either prophylactically or targeted at infants with tran-
sient hypothyroxinaemia, found no evidence of effect onmortality
or neurodevelopment, or on the severity of respiratory distress syn-
drome or the incidence of CLD, in very preterm infants (Osborn
2007a; Osborn 2007b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available trial data indicate that iodine supplementation does
not reduce mortality and morbidity in very preterm infants.
Implications for research
There is no longer a need for further randomised controlled trials
to determine if iodine supplementation, started within a few days
after birth, prevents morbidity and mortality in preterm infants.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Rogahn 2000
Methods Randomised controlled trial
Study sites: 5 neonatal units in the Mersey region, UK (1997-1998)
Participants Newborn infants < 33 weeks’ gestation at birth
Interventions Treatment (n = 61): iodide supplemented “preterm” formula milk (272 µg/L)
Control (n = 60): same milk without iodine supplementation: iodine concentration 68
µg/L
Allocated formula continued until infants reached 40 to 41 weeks’ postmenstrual age
Outcomes Primary: plasma levels of TSH, total thyroxine, total tri-iodothyronine, and, when pos-
sible, T4
Secondary: volume of milk ingested; weekly change in weight, leg length, and head cir-
cumference during trial; mortality; respiratory outcomes (days ventilated, days requiring
supplemental oxygen therapy, incidence of CLD); incidence of severe intraventricular
haemorrhage and cystic periventricular leukomalacia; duration of hospital admission
(days)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified according to birthweight (< 1000
g and ≥ 1000 g) using a 2- and 4-block
design generated by randomised number
tables
Allocation concealment (selection bias) Low risk Allocation sealed in opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study milks indistinguishable in appear-
ance.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessment blinded to trial
group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 10% loss to follow-up.
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Rogahn 2000 (Continued)
Selective reporting (reporting bias) Unclear risk Number of days of continuous positive air-
ways pressure; number of days until com-
pleting the study; duration of parenteral
feeding and human milk feeding in days;
and daily milk intake in millilitres prespec-
ified but not reported
Williams 2017
Methods Randomised controlled trial
Study sites: 21 neonatal units in the UK (2010-2012)
Participants Newborn infants < 31 weeks’ gestation at birth
Interventions Treatment (n = 637): sodium iodide given enterally or parenterally at 30 µg/kg/day
Control (n = 636): sodium chloride given enterally or parenterally at 30 µg/kg/day
Allocated trial solution continued until infants reached 34 weeks’ gestational age
Outcomes Primary: neurodevelopmental status defined by the Cognitive, Language, and Motor
domains of the Bayley-III at 2 years of age corrected for prematurity
Secondary: *mortality, subtests of Bayley-III; Bayley-III analysed as a dichotomous out-
come (death or Bayley-III score < 85 in any of the main domains versus Bayley-III score
≥ 85); plasma levels of T4, TSH, TBG up to 34-36 weeks’ postmenstrual age; neonatal
morbidity (RDS, CLD, PDA, NEC, hyperbilirubinaemia, acquired infections, cerebral
pathology closest to 34 weeks’, porencephalic cyst, cystic periventricular leukomalacia,
ventriculopleural)
Notes 1275 infants randomised. 2 infants randomised in error (n = 1273), 14 withdrawals (6
in iodine group, 8 in placebo group, no data used); sample size of 631 in iodine group
and 628 in placebo group (n = 1259)
*(61 infants in iodide group and 59 infants in placebo group died during the intervention
stage of the trial, and 65 infants in iodide group and 66 infants in placebo group died
before 2-year follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation programme using “be-
spoke minimization algorithm to ensure
balance across hospitals on gender and ges-
tational age.”
Allocation concealment (selection bias) Low risk Allocation via “a secure website with tele-
phone backup.”
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Williams 2017 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Packaging and visual appearance
of trial solutions were identical.”
Research team, trial statistician, parents,
neonatal staff, and pharmacy blinded to
content of trial solutions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessment blinded to trial
group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 10% loss to follow-up.
Selective reporting (reporting bias) Unclear risk Days of endotracheal intubation and days
of continuous positive airways pressure pre-
specified but not reported
Bayley-III: Bayley Scales of Infant and Toddler Development, Third Edition; CLD: chronic lung disease; n: number of participants;
NEC: necrotising enterocolitis; PDA: persistent ductus arteriosus; RDS: respiratory distress syndrome; T4: free thyroxine; TBG:
thyroid-binding globulin; TSH: thyroid-stimulating hormone.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Belykh 2014 Reported as a conference abstract. Iodine given to mother during pregnancy and lactation. Likely that infant
supplementation given via mother and iodine was not added to breast milk directly
Bouhouch 2013 Likely to be a trial restricted to term rather than preterm infants. Compared iodine supplementation for moth-
ers versus iodine supplementation for infants (i.e. maternal supplementation was the control rather than no
supplementation)
Karto lu 2014 Gestation of participants not specified, and trial compared treatment of infants with congenital hypothyroidism
Mohammed 2015 Cluster randomised controlled trial of iodised salt given to pregnant women (rather than infants) in Ethiopia
Wang 2013 Chinese language report with English abstract. Likely to have been a cluster randomised controlled trial of effect
of community-based iodine supplementation for children up to 3 years old on neurodevelopment
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D A T A A N D A N A L Y S E S
Comparison 1. Iodine supplementation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality before hospital
discharge
2 1380 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.72, 1.42]
2 Bayley-III Cognitive score at
2 years of age corrected for
prematurity
1 1259 Mean Difference (IV, Fixed, 95% CI) -0.30 [-2.44, 1.84]
3 Bayley-III Motor composite
score at 2 years of age corrected
for prematurity
1 1259 Mean Difference (IV, Fixed, 95% CI) 0.20 [-2.15, 2.55]
4 Bayley-III Language composite
score at 2 years of age corrected
for prematurity
1 1259 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.50, 2.30]
5 Low score in any main Bayley
domain (< 85) or death
1 1259 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.94, 1.17]
6 Visual impairment 1 1092 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.28, 1.45]
7 Auditory impairment 1 1093 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.51, 2.16]
8 Air leaks (pneumothorax) 1 1257 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.31, 0.80]
9 Chronic lung disease in surviving
infants (supplemental oxygen
requirement at 36 weeks’
postmenstrual age)
2 1377 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.94, 1.22]
10 Necrotising enterocolitis 1 1259 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.98, 1.56]
11 Retinopathy of prematurity 1 1257 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.64, 1.49]
12 Persistent ductus arteriosus 1 1259 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.83, 1.16]
13 Late-onset infection 1 1259 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.96, 1.24]
14 Total plasma thyroxine
(nmol/L) at 34-36 weeks’
postmenstrual age
2 1121 Mean Difference (IV, Fixed, 95% CI) 0.29 [-1.51, 2.09]
15 Thyroid-stimulating hormone
(mU/L) at 34-36 weeks’
postmenstrual age
2 1119 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.09, 0.18]
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Analysis 1.1. Comparison 1 Iodine supplementation versus control, Outcome 1 Mortality before hospital
discharge.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 1 Mortality before hospital discharge
Study or subgroup Iodine supplemented Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rogahn 2000 0/61 1/60 2.5 % 0.33 [ 0.01, 7.89 ]
Williams 2017 61/631 59/628 97.5 % 1.03 [ 0.73, 1.45 ]
Total (95% CI) 692 688 100.0 % 1.01 [ 0.72, 1.42 ]
Total events: 61 (Iodine supplemented), 60 (Control)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours iodine Favours control
Analysis 1.2. Comparison 1 Iodine supplementation versus control, Outcome 2 Bayley-III Cognitive score at
2 years of age corrected for prematurity.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 2 Bayley-III Cognitive score at 2 years of age corrected for prematurity
Study or subgroup Iodine supplemented Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Williams 2017 631 88.9 (19.2) 628 89.2 (19.5) 100.0 % -0.30 [ -2.44, 1.84 ]
Total (95% CI) 631 628 100.0 % -0.30 [ -2.44, 1.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours iodine
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Analysis 1.3. Comparison 1 Iodine supplementation versus control, Outcome 3 Bayley-III Motor composite
score at 2 years of age corrected for prematurity.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 3 Bayley-III Motor composite score at 2 years of age corrected for prematurity
Study or subgroup Iodine supplemented Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Williams 2017 631 88.2 (21) 628 88 (21.6) 100.0 % 0.20 [ -2.15, 2.55 ]
Total (95% CI) 631 628 100.0 % 0.20 [ -2.15, 2.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours control Favours iodine
Analysis 1.4. Comparison 1 Iodine supplementation versus control, Outcome 4 Bayley-III Language
composite score at 2 years of age corrected for prematurity.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 4 Bayley-III Language composite score at 2 years of age corrected for prematurity
Study or subgroup Iodine supplemented Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Williams 2017 631 85.1 (21.7) 628 85.2 (21.8) 100.0 % -0.10 [ -2.50, 2.30 ]
Total (95% CI) 631 628 100.0 % -0.10 [ -2.50, 2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours iodine
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Analysis 1.5. Comparison 1 Iodine supplementation versus control, Outcome 5 Low score in any main
Bayley domain (< 85) or death.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 5 Low score in any main Bayley domain (< 85) or death
Study or subgroup Iodine supplemented Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 325/631 308/628 100.0 % 1.05 [ 0.94, 1.17 ]
Total (95% CI) 631 628 100.0 % 1.05 [ 0.94, 1.17 ]
Total events: 325 (Iodine supplemented), 308 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours iodine Favours control
Analysis 1.6. Comparison 1 Iodine supplementation versus control, Outcome 6 Visual impairment.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 6 Visual impairment
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 9/551 14/541 100.0 % 0.63 [ 0.28, 1.45 ]
Total (95% CI) 551 541 100.0 % 0.63 [ 0.28, 1.45 ]
Total events: 9 (Iodine), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
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Analysis 1.7. Comparison 1 Iodine supplementation versus control, Outcome 7 Auditory impairment.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 7 Auditory impairment
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 15/551 14/542 100.0 % 1.05 [ 0.51, 2.16 ]
Total (95% CI) 551 542 100.0 % 1.05 [ 0.51, 2.16 ]
Total events: 15 (Iodine), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours iodine Favours control
Analysis 1.8. Comparison 1 Iodine supplementation versus control, Outcome 8 Air leaks (pneumothorax).
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 8 Air leaks (pneumothorax)
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 25/629 50/628 100.0 % 0.50 [ 0.31, 0.80 ]
Total (95% CI) 629 628 100.0 % 0.50 [ 0.31, 0.80 ]
Total events: 25 (Iodine), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
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Analysis 1.9. Comparison 1 Iodine supplementation versus control, Outcome 9 Chronic lung disease in
surviving infants (supplemental oxygen requirement at 36 weeks’ postmenstrual age).
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 9 Chronic lung disease in surviving infants (supplemental oxygen requirement at 36 weeks’ postmenstrual age)
Study or subgroup Iodine supplemented Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rogahn 2000 16/61 24/59 9.4 % 0.64 [ 0.38, 1.09 ]
Williams 2017 262/629 235/628 90.6 % 1.11 [ 0.97, 1.28 ]
Total (95% CI) 690 687 100.0 % 1.07 [ 0.94, 1.22 ]
Total events: 278 (Iodine supplemented), 259 (Control)
Heterogeneity: Chi2 = 3.94, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
Analysis 1.10. Comparison 1 Iodine supplementation versus control, Outcome 10 Necrotising enterocolitis.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 10 Necrotising enterocolitis
Study or subgroup Iodine suppliment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 128/631 103/628 100.0 % 1.24 [ 0.98, 1.56 ]
Total (95% CI) 631 628 100.0 % 1.24 [ 0.98, 1.56 ]
Total events: 128 (Iodine suppliment), 103 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
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Analysis 1.11. Comparison 1 Iodine supplementation versus control, Outcome 11 Retinopathy of
prematurity.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 11 Retinopathy of prematurity
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 39/629 40/628 100.0 % 0.97 [ 0.64, 1.49 ]
Total (95% CI) 629 628 100.0 % 0.97 [ 0.64, 1.49 ]
Total events: 39 (Iodine), 40 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
Analysis 1.12. Comparison 1 Iodine supplementation versus control, Outcome 12 Persistent ductus
arteriosus.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 12 Persistent ductus arteriosus
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 192/631 195/628 100.0 % 0.98 [ 0.83, 1.16 ]
Total (95% CI) 631 628 100.0 % 0.98 [ 0.83, 1.16 ]
Total events: 192 (Iodine), 195 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
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Analysis 1.13. Comparison 1 Iodine supplementation versus control, Outcome 13 Late-onset infection.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 13 Late-onset infection
Study or subgroup Iodine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2017 283/631 258/628 100.0 % 1.09 [ 0.96, 1.24 ]
Total (95% CI) 631 628 100.0 % 1.09 [ 0.96, 1.24 ]
Total events: 283 (Iodine), 258 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours iodine Favours control
Analysis 1.14. Comparison 1 Iodine supplementation versus control, Outcome 14 Total plasma thyroxine
(nmol/L) at 34-36 weeks’ postmenstrual age.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 14 Total plasma thyroxine (nmol/L) at 34 36 weeks’ postmenstrual age
Study or subgroup Iodine supplemented Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rogahn 2000 56 120 (31) 54 120 (24) 3.0 % 0.0 [ -10.34, 10.34 ]
Williams 2017 504 47.2 (15.1) 507 46.9 (14.5) 97.0 % 0.30 [ -1.53, 2.13 ]
Total (95% CI) 560 561 100.0 % 0.29 [ -1.51, 2.09 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours iodine Favours control
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Analysis 1.15. Comparison 1 Iodine supplementation versus control, Outcome 15 Thyroid-stimulating
hormone (mU/L) at 34-36 weeks’ postmenstrual age.
Review: Iodine supplementation for the prevention of mortality and adverse neurodevelopmental outcomes in preterm infants
Comparison: 1 Iodine supplementation versus control
Outcome: 15 Thyroid-stimulating hormone (mU/L) at 34 36 weeks’ postmenstrual age
Study or subgroup Iodine supplemented Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rogahn 2000 54 1.93 (0.91) 54 2.13 (1.58) 7.8 % -0.20 [ -0.69, 0.29 ]
Williams 2017 504 1.59 (1.23) 507 1.52 (1.05) 92.2 % 0.07 [ -0.07, 0.21 ]
Total (95% CI) 558 561 100.0 % 0.05 [ -0.09, 0.18 ]
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours iodine Favours control
A P P E N D I C E S
Appendix 1. Search strategy
Databases searched
CENTRAL 459 records
MEDLINE 1887 records
Embase 1292 records
Maternity & Infant Care 27 records
CINAHL 353 records
[Trials registers: ClinicalTrials.gov and WHO ICTRP (45 and 14 records)]
MEDLINE
Via Ovid
Search date 27 February 2018
1887 records
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process and Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R) <1946 to Present>
1 Iodine/ (24063)
2 Iodine$.ti,ab. (43673)
3 Iodides/ (9638)
4 Iodide$.ti,ab. (31252)
5 Potassium Iodide/ (1961)
6 exp Thyroid Hormones/ (61903)
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7 (thyroid adj2 hormone$).ti,ab. (41896)
8 exp dextrothyroxine/ or exp diiodotyrosine/ or exp monoiodotyrosine/ or exp “thyroid (usp)”/ or exp thyronines/ or exp thyroxine/
or triiodothyronine/ (47871)
9 dextrothyroxine$.ti,ab. (82)
10 diiodotyrosine$.ti,ab. (384)
11 monoiodotyrosine$.ti,ab. (233)
12 (thyroid adj2 usp).ti,ab. (10)
13 thyronine$.ti,ab. (1493)
14 thyroxine$.ti,ab. (25721)
15 L-thyroxine therap$.ti,ab. (212)
16 hypothyroxin$.ti,ab. (535)
17 triiodothyronine$.ti,ab. (15979)
18 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (162174)
19 exp Infant, Newborn/ (561814)
20 Premature Birth/ (10565)
21 (neonat$ or neo nat$).ti,ab. (235139)
22 (newborn$ or new born$ or newly born$).ti,ab. (151502)
23 (preterm or preterms or pre term or pre terms).ti,ab. (62750)
24 (preemie$ or premie or premies).ti,ab. (145)
25 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (14033)
26 (low adj3 (birthweight$ or birth weight$)).ti,ab. (30911)
27 (lbw or vlbw or elbw).ti,ab. (7222)
28 infan$.ti,ab. (392750)
29 (baby or babies).ti,ab. (62792)
30 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (961691)
31 18 and 30 (8059)
32 randomized controlled trial.pt. (454398)
33 controlled clinical trial.pt. (92180)
34 randomized.ab. (404232)
35 placebo.ab. (186767)
36 drug therapy.fs. (1995838)
37 randomly.ab. (285844)
38 trial.ab. (419845)
39 groups.ab. (1768325)
40 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 (4149324)
41 exp animals/ not humans.sh. (4429349)
42 40 not 41 (3585184)
43 31 and 42 (1892)
Embase
Via Ovid
Search date 27 February 2018
1292 records
Database: Embase <1974 to 2018 Week 09>
1 Iodine/ (40146)
2 Iodine$.ti,ab. (53091)
3 Iodide/ (10272)
4 Iodide$.ti,ab. (38417)
5 Potassium Iodide/ (4652)
6 thyroid hormone/ (30585)
7 (thyroid adj2 hormone$).ti,ab. (51589)
8 dextrothyroxine/ (525)
9 diiodotyrosine/ (863)
10 Iodotyrosine/ (805)
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11 “thyroid usp”/ (590)
12 thyroxine/ (52309)
13 Iodothyronine/ (846)
14 thyroid extract/ (639)
15 thyronine derivative/ (399)
16 dextrothyroxine$.ti,ab. (79)
17 diiodotyrosine$.ti,ab. (387)
18 monoiodotyrosine$.ti,ab. (253)
19 (thyroid adj2 usp).ti,ab. (11)
20 thyronine$.ti,ab. (1544)
21 thyroxine$.ti,ab. (29804)
22 L-thyroxine therap$.ti,ab. (282)
23 hypothyroxin$.ti,ab. (703)
24 triiodothyronine$.ti,ab. (17472)
25 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
(208650)
26 Newborn/ (535958)
27 Prematurity/ (91912)
28 (neonat$ or neo nat$).ti,ab. (302978)
29 (newborn$ or new born$ or newly born$).ti,ab. (184831)
30 (preterm or preterms or pre term or pre terms).ti,ab. (86501)
31 (preemie$ or premie or premies).ti,ab. (214)
32 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (18987)
33 (low adj3 (birthweight$ or birth weight$)).ti,ab. (38449)
34 (lbw or vlbw or elbw).ti,ab. (9722)
35 infan$.ti,ab. (460657)
36 (baby or babies).ti,ab. (85582)
37 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 (1082447)
38 25 and 37 (11309)
39 (random* or factorial* or placebo* or assign* or allocat* or crossover*).tw. (1659186)
40 (cross adj over*).tw. (28819)
41 (trial* and (control* or comparative)).tw. (503252)
42 ((blind* or mask*) and (single or double or triple or treble)).tw. (234368)
43 (treatment adj arm*).tw. (16210)
44 (control* adj group*).tw. (550749)
45 (phase adj (III or three)).tw. (51245)
46 (versus or vs).tw. (1733178)
47 rct.tw. (27329)
48 Crossover Procedure/ (54400)
49 Double Blind Procedure/ (146612)
50 Single Blind Procedure/ (30461)
51 Randomization/ (77056)
52 Placebo/ (319921)
53 exp Clinical Trial/ (1295328)
54 Parallel Design/ (7954)
55 Latin Square Design/ (359)
56 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 (4258513)
57 exp animal/ or exp nonhuman/ or exp animal experiment/ or exp animal model/ (25585217)
58 exp human/ (19276078)
59 57 not 58 (6309139)
60 56 not 59 (3698276)
61 38 and 60 (1292)
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Via Wiley’s Cochrane Library
Search date 27 February 2018
Records retrieved= 459
#1 MeSH descriptor: [Iodine] explode all trees
#2 iodine*:ti,ab,kw (Word variations have been searched)
#3 MeSH descriptor: [Iodides] explode all trees
#4 iodide*:ti,ab,kw (Word variations have been searched)
#5 MeSH descriptor: [Potassium Iodide] explode all trees
#6 MeSH descriptor: [Thyroid Hormones] explode all trees
#7 thyroid near/2 hormone*:ti,ab,kw (Word variations have been searched)
#8 MeSH descriptor: [Dextrothyroxine] explode all trees
#9 MeSH descriptor: [Diiodotyrosine] explode all trees
#10 MeSH descriptor: [Monoiodotyrosine] explode all trees
#11 MeSH descriptor: [Thyroid (USP)] explode all trees
#12 MeSH descriptor: [Thyronines] explode all trees
#13 MeSH descriptor: [Thyroxine] explode all trees
#14 MeSH descriptor: [Triiodothyronine] explode all trees
#15 dextrothyroxine*:ti,ab,kw or diiodotyrosine*:ti,ab,kw or monoiodotyrosine*:ti,ab,kw or thyroid near/2 usp:ti,ab,kw or thyronine*:
ti,ab,kw (Word variations have been searched)
#16 thyroxine*:ti,ab,kw or L-thyroxine therap*:ti,ab,kw or Hypothyroxin*:ti,ab,kw or triiodothyronine*:ti,ab,kw (Word variations
have been searched)
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Infant, Newborn] explode all trees
#19 MeSH descriptor: [Premature Birth] explode all trees
#20 neonat*:ti,ab,kw (Word variations have been searched)
#21 neo-nat*:ti,ab,kw (Word variations have been searched)
#22 newborn or new born* or newly born*:ti,ab,kw (Word variations have been searched)
#23 preterm or preterms or (pre term) or (pre terms):ti,ab,kw (Word variations have been searched)
#24 preemie* or premie or premies:ti,ab,kw (Word variations have been searched)
#25 prematur* near/3 (birth* or born or deliver*):ti,ab,kw (Word variations have been searched)
#26 low near/3 (birthweight* or birth weight*):ti,ab,kw (Word variations have been searched)
#27 lbw or vlbw or elbw:ti,ab,kw (Word variations have been searched)
#28 infan* or baby or babies:ti,ab,kw (Word variations have been searched)
#29 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30 #17 and #29
Maternity & Infant Care
Via Ovid
Search date 27 February 2018
Records retrieved= 27
Database: Maternity & Infant Care Database (MIDIRS) <1971 to December 2017>
1 Iodine.de. (102)
2 iodine$.ti,ab. (402)
3 iodides.de. (4)
4 iodide$.ti,ab. (28)
5 potassium iodide$.de,ti,ab. (0)
6 thyroid hormone$.de,ti,ab. (323)
7 dextrothyroxine.de,ti,ab. (0)
8 diiodotyrosine.de,ti,ab. (0)
9 monoiodotyrosine.de,ti,ab. (0)
10 (thyroid adj2 usp).de,ti,ab. (0)
11 thyronines.de,ti,ab. (0)
12 thyroxine.de,ti,ab. (355)
13 triiodothyronine.de,ti,ab. (79)
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14 L-thyroxine therap$.de,ti,ab. (3)
15 hypothyroxin$.de,ti,ab. (92)
16 triiodothyronine$.de,ti,ab. (79)
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (905)
18 limit 17 to randomised controlled trial (27)
CINAHL
Via EBSCO
Search date 27 February 2018
Records retrieved = 353 records
S1 (MH “iodine”) Results 1721
S2 TX iodine* View Results (5,940)
View Details
Edit
S3 (MH “Iodides+”) OR (MH “Potassium Iodide”) View Results (219)
View Details
Edit
S4 TX iodide* View Results (958)
View Details
Edit
S5 (MH “Thyroid Hormones+”) View Results (3,047)
View Details
Edit
S6 TX thyroid N2 hormone* View Results (3,248)
View Details
Edit
S7 (MH “Thyronines+”) View Results (412)
View Details
Edit
S8 (MH “Thyroxine+”) View Results (1,896)
View Details
Edit
S9 (MH “Triiodothyronine”) View Results (399)
View Details
Edit
S10 TX dextrothyroxine* OR TX diiodotyrosine* OR TX
monoiodotyrosine* OR TX thyroid N2 usp OR TX thyro-
nine* ORTX thyroxine* OR TX L-thyroxine N2 therap* OR
TX hypothyroxin* OR TX triiodothyronine*
View Results (2,611)
View Details
Edit
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(Continued)
S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR
S9 OR S10
View Results (10,887)
View Details
Edit
S12 (MH “Infant, Newborn+”) Rerun
View Details
Edit
S13 TX ( (neonat* or neo nat*) )ORTX ( (newborn* or new born*
or newly born*) ) OR TX ( (preterm or preterms or pre term
or pre terms) ) OR TX ( (preemie$ or premie or premies) )
OR TX ( (prematur* NEAR/3 (birth* or born or deliver*)) )
OR TX ( (low NEAR/3 (birthweight* or birth weight*)) ) OR
TX ( (lbw or vlbw or elbw) ) OR TX infan* OR TX ( (baby
or babies) )
Rerun
View Details
Edit
S14 S12 OR S13 Rerun
View Details
Edit
S15 S11 AND S14 View Results (1,376)
View Details
Edit
S16 (MH “Randomized Controlled Trials”) OR (MH “Clinical
Trials+”)
View Results (235,417)
View Details
Edit
S17 TI randomiz* OR AB randomiz* OR TI randomis* OR AB
randomis* OR AB placebo ORAB randomly OR AB trial OR
AB groups
View Results (664,541)
View Details
Edit
S18 S16 OR S17 View Results (760,646)
View Details
Edit
S19 S15 AND S18 View Results (353)
View Details
Trials registers - ClinicalTrials.gov and WHO ICTRP
Clinicaltrials.gov
https://clinicaltrials.gov/ct2/home
Search date 27 February 2018
45 unique records identified
Two searches
Search one
Intervention search = Dietary supplement: Iodine, limited to child and interventional studies
Search two
Condition search = Iodine deficiency, limited to child and interventional studies
WHO ICTRP
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http://apps.who.int/trialsearch/Default.aspx
Search date 27 February 2018
14 unique records
Search 1 Iodine deficiency [condition] 9 records for 8 trials
Search 2 ((pregnant OR pregnancy OR prenatal OR women OR woman OR mother OR mothers OR maternal OR lactation OR
lactating [title]) AND (Iodine [intervention])) 7 records
Appendix 2. Risk of bias tool
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
• low risk (any truly random process, e.g. random number table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or
• unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
• unclear risk.
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding was assessed separately for different outcomes or class of outcomes. We categorised the
methods as:
• low risk, high risk, or unclear risk for participants; and
• low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we categorised the methods used to blind outcome assessment. Blinding was assessed separately for different
outcomes or class of outcomes. We categorised the methods as:
• low risk for outcome assessors;
• high risk for outcome assessors; or
• unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were
incomplete outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with
the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across
groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we reincluded missing
data in the analyses. We categorised the methods as:
• low risk (less than 20% missing data);
• high risk (20% or greater missing data); or
• unclear risk.
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. For
studies in which study protocols were published in advance, we compared prespecified outcomes versus outcomes eventually reported
in the published results. If the study protocol was not published in advance, we contacted study authors to gain access to the study
protocol. We assessed the methods as:
• low risk (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have
been reported);
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• high risk (where not all the study’s prespecified outcomes were reported; one or more reported primary outcomes were not
prespecified outcomes of interest and were reported incompletely and so could not be used; study failed to include results of a key
outcome that would have been expected to have been reported); or
• unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at a high risk of bias?
For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a
potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process).
We assessed whether each study was free of other problems that could put it at risk of bias as:
• low risk;
• high risk; or
• unclear risk.
If needed, we explored the impact of the level of bias through undertaking sensitivity analyses.
Appendix 3. GRADE
GRADE considers that evidence from randomised controlled trials is ’high’ quality but that assessment may be downgraded based on
consideration of any of five areas:
• design (risk of bias);
• consistency across studies;
• directness of the evidence;
• precision of estimates; and
• presence of publication bias.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
WH A T ’ S N E W
Date Event Description
18 February 2019 New search has been performed Updated to include new trial and newer methods, in-
cluding ’Summary of findings’ table
7 June 2018 New citation required and conclusions have changed One new trial included (Williams 2017).
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H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 2, 2006
Date Event Description
18 September 2008 Amended Converted to new review format.
14 February 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
VW and WM undertook the electronic and handsearches. VW and JVEB screened the title and abstract of all studies identified, and
the full text of the report identified as of potential relevance.
VW and JVEB assessed the methodological quality of the included trials, and extracted the relevant information and data.
WM resolved disagreements.
All three authors completed the final review.
D E C L A R A T I O N S O F I N T E R E S T
VW: none.
JVEB: none.
WG: none.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Vermont Oxford Network, USA.
Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a worldwide collaboration of health
professionals dedicated to providing evidence-based care of the highest quality for newborn infants and their families.
• National Institute for Health Research (NIHR), UK.
This report is independent research funded by a UK NIHR Cochrane Programme Grant (16/114/03). The views expressed in this
publication are those of the review authors and are not necessarily those of the National Health Service, the NIHR, or the UK
Department of Health.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements; Developmental Disabilities [etiology; ∗prevention & control]; Enteral Nutrition; Infant Mortality; Infant,
Premature; Iodine [∗administration & dosage; ∗deficiency]; Parenteral Nutrition
MeSH check words
Humans; Infant, Newborn
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